0.86Open0.86Pre Close8 Volume0 Open Interest10.00Strike Price739.00Turnover380.92%IV58.68%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry1.03Extrinsic Value100Contract SizeAmericanOptions Type-0.0995Delta0.0082Gamma13.36Leverage Ratio-0.0773Theta-0.0022Rho-1.33Eff Leverage0.0097Vega
Jasper Therapeutics Stock Discussion
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
14 of 15 participants enrolled achieved a clinical response
10 of 12 participants in the 120mg cohort achieved a complete response
No serious adverse events; no grade 3 or higher adverse events reported
Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort
Company to host conference call and webinar today at 8:00 ...
Microsoft $Microsoft (MSFT.US)$ (office currently has nearly 400 million users, OficARPU increases after the acquisition of OpenA and Azurez-related...
No comment yet